Guohai Securities released a research report on April 23 stating that it gave Jiete Biotech (688026.SH) a purchase rating. The main reasons for the rating include: 1) slow recovery in overseas market demand and declining company performance; 2) actively promoting the implementation of fund-raising projects and continuing to improve core technology; 3) improving independent brand building and extending the layout of medical supplies and equipment. (Mainichi Keizai Shimbun)
国海证券4月23日发布研报称，给予洁特生物（688026.SH）买入评级。评级理由主要包括：1）海外市场需求恢复缓慢，公司业绩下降；2）积极推进募投项目落地实施，核心技术持续提升；3）提升自主品牌建设，延伸布局医疗耗材及设备。（每日经济新闻）
Guohai Securities released a research report on April 23 stating that it gave Jiete Biotech (688026.SH) a purchase rating. The main reasons for the rating include: 1) slow recovery in overseas market demand and declining company performance; 2) actively p
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.